老年人骨质疏松性骨折治疗药物研究进展(2)
[3]蔡久波,白云,肖明.骨质疏松性骨折治疗药物研究进展[J].实用医药杂志,2006,23(2):228.
[4]Neer RM,Arnaud CD,Zanchetta JR,et al.Effect of parathy-roid hormone(1-34)on fractures and bone mineral density in postmenopausal women with osteoporosis[J].N Engl J Med,2001,344:1434.
[5]Levis S,Quandt SA,Thompson D,et al.Alendronate reduces the risk of multiple symptomatic fracture:results from theFracture Intervention Trial[J].J Am Geriatr Soc,2002,50:409.
[6]Reginster J,Minne HW,Sorensen OH,et al.Randomized trial of the effects of risedronate on vertebral fractures in women with establishedpostmenopausal osteoporosis.Vertebral Effica-cy With Risedronate Therapy(VERT)Study Group[J].Osteoporos Int,2000,11:83.
[7]Watts NB,Adami S,Chesnut C.Risedronate reduces the risk of clinical vertebral fractures in just 6 months[J].J Bone Miner Res,2001,16(suppl 1):s407.
[8]Harrington JT,Eastell R,Barton IP,Bolognese MA.Risedronate significantly reduces nonvertebral fractures as soon as 6 months in postmenopausal osteoporosis[C].Presented at:84th Annual Meeting of the Endocrine Society,2002.
[9]US Preventive Services Task Force.Screening for osteoporosis in postmenopausal women:recommendations and rationale[J].Ann Intern Med,2002,137:526.
[10]Worley K,Doyle J,Sheer R,et al.Incidence of gastrointesti- nal events among osteoporotic patients treated with bisphos- phonates[J].JMCP,2003,9:193.
(收稿日期:2008-12-26), 百拇医药(朱艳玲)
[4]Neer RM,Arnaud CD,Zanchetta JR,et al.Effect of parathy-roid hormone(1-34)on fractures and bone mineral density in postmenopausal women with osteoporosis[J].N Engl J Med,2001,344:1434.
[5]Levis S,Quandt SA,Thompson D,et al.Alendronate reduces the risk of multiple symptomatic fracture:results from theFracture Intervention Trial[J].J Am Geriatr Soc,2002,50:409.
[6]Reginster J,Minne HW,Sorensen OH,et al.Randomized trial of the effects of risedronate on vertebral fractures in women with establishedpostmenopausal osteoporosis.Vertebral Effica-cy With Risedronate Therapy(VERT)Study Group[J].Osteoporos Int,2000,11:83.
[7]Watts NB,Adami S,Chesnut C.Risedronate reduces the risk of clinical vertebral fractures in just 6 months[J].J Bone Miner Res,2001,16(suppl 1):s407.
[8]Harrington JT,Eastell R,Barton IP,Bolognese MA.Risedronate significantly reduces nonvertebral fractures as soon as 6 months in postmenopausal osteoporosis[C].Presented at:84th Annual Meeting of the Endocrine Society,2002.
[9]US Preventive Services Task Force.Screening for osteoporosis in postmenopausal women:recommendations and rationale[J].Ann Intern Med,2002,137:526.
[10]Worley K,Doyle J,Sheer R,et al.Incidence of gastrointesti- nal events among osteoporotic patients treated with bisphos- phonates[J].JMCP,2003,9:193.
(收稿日期:2008-12-26), 百拇医药(朱艳玲)